Patent Assignment
Reel/Frame 041328/0362
Assignment of Assignor's Interest
Recorded: 2017-01-11
Pages: 6
Assignor
TAKEDA GMBH
Executed: 2016-04-29
Assignee
ASTRAZENECA AB
SÖDERTÄLJE, SÖDERTÄLJE, SE 151 85, SWEDEN
Covered Properties
(55)
New Pregna-1,4-DIENE3,20-Dione-16-17-Acetal-21 Esters, Process for Their Preparation, Composition, and Methods for the Treatment of Inflammatory Conditions
Patent:
5,482,934 →
Application:
08/278,112 →
Fluoroalkoxy-Substituted Benzamides and Their Use as Cyclic Nucleotide Phosphodiesterase Inhibitors
Patent:
5,712,298 →
Application:
08/564,322 →
Process for R-Epimer Enrichment of 16,17-Acetal Derivatives of 21-Acyloxy Pregna-1,4-Dien-11.Beta. , 16.Alpha. , 17.Alpha.-Triol-3,20-Dione Derivatives
Patent:
6,787,533 →
Application:
09/147,675 →
Synergistic Combination of Pde Inhibitors and Adenylate Cyclase Agonists or Guanyl Cyclyse Agonists
Patent:
6,333,354 →
Application:
09/367,850 →
Compositions for the Treatment of Ards or Irds Containing 3- (Cyclopropylmethoxy) -N- (3,5-Dichloro-4-Pyridinyl) -4- (Difluoromethoxy) Benzamide and Lung Surfactant
Patent:
6,436,970 →
Application:
09/369,455 →
Synergistic Combination
Patent:
6,624,181 →
Application:
10/049,999 →
Novel Compositions
Ciclesonide Contained Pharmaceutical Composition for Application to Mucosa
Patent:
6,767,901 →
Application:
10/110,629 →
Ciclesonide Containing Aqueous Pharmaceutical Composition
Patent:
8,383,611 →
Application:
10/110,632 →
Process for the Production of 16,17-[{Cyclohexylmethylen)Bis(Oxy)]-11,21-Dihydroxy-Pregna-1,4-Dien-3,20-Dion or Its 21-Isobutyrat by Transketalisation
Pharmaceutical Preparation Comprising an Active Dispersed on a Matrix
Synergistic Combination
Oral Dosage Form Containing a Pde 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient
Ciclesonide-Containing Sterile Aqueous Suspension
Use of the Combination of Ciclesonide and Antihistamines for the Treatment of Allergic Rhinitis
Novel Process for the Preparation of Roflumilast
Combination Medicament
Process for preparing crystalline ciclesonide with defined particle size
Formoterol and Ciclesonide Combination
Use of PDE4 Inhibitors for the Treatment of Diabetes Mellitus
Use of Ciclesonide for the Treatment of Respiratory Diseases
Compliance monitor and method
Stabilized Pharmaceutical Product
Stable Pharmaceutical Products
Use of Ciclesonide for the Treatment of Respiratory Diseases in a Smoking Patient
Application:
11/578,294 →
Publication:
US 2007/0134165
Pharmaceutical Preparation Comprising an Active Dispersed on a Matrix
Aqueous Pharmaceutical Preparation Comprising Roflumilast
Roflumilast for the Treatment of Diabetes Mellitus
Taste Masked Dosage Form Containing Roflumilast
Roflumilast for the Treatment of Pulmonary Hypertension
Combination of a Nsaid and a Pde-4 Inhibitor
Ciclesonide containing sterile aqueous suspension
Ciclesonide-Containing Sterile Aqueous Suspension
Stabilized Pharmaceutical Product
Stable Pharmaceutical Products
Combination Medicament
Use of the Combination of Ciclesonide and Antihistamines for the Treatment of Allergic Rhinitis
Oral Dosage Form Containing a Pde 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidone as Excipient
Roflumilast for the Treatment of Diabetes Mellitus Type 2
Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor
Application:
13/216,936 →
Publication:
US 2012/0052122
Stabilized Pharmaceutical Product
Stabilized Pharmaceutical Product
Novel Process for the Preparation of Roflumilast
Ciclesonide Containing Aqueous Pharmaceutical Composition
Application:
13/688,659 →
Publication:
US 2013/0095146
Use of Ciclesonide for the Treatment of Respiratory Diseases
Application:
13/744,962 →
Publication:
US 2013/0143849
Novel Process For The Preparation Of Roflumilast
Novel Process for the Preparation of Roflumilast
Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient
Application:
14/038,666 →
Publication:
US 2014/0031396
Topically Applicable Pharmaceutical Preparation
Application:
14/075,035 →
Publication:
US 2014/0303215
Pharmaceutical Aerosol Product for Administration by Oral or Nasal Inhalation
Combination of Hmg-Coa Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Diseases
Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient
Application:
14/731,964 →
Publication:
US 2015/0290178
Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient
Application:
14/735,004 →
Publication:
US 2015/0290179
Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient
Application:
14/735,015 →
Publication:
US 2015/0290180
Aqueous Suspensions of Ciclesonide for Nebulisation
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Change of Name
Sep 4, 2007
From: ALTANA PHARMA AG
To: NYCOMED GMBH
Reel/Frame 019781/0225 →
Change of Name
Sep 4, 2007
From: ALTANA PHARMA AG
To: NYCOMED GMBH
Reel/Frame 019783/0625 →
Change of Name
Mar 26, 2013
From: NYCOMED GMBH
To: TAKEDA GMBH
Reel/Frame 030091/0737 →
Merger
Jan 30, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 034869/0936 →
Change of Name
Jan 30, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 034862/0060 →
Merger
Jan 30, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 034869/0899 →
Merger
Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0224 →
Merger
Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0178 →
Merger
Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0261 →
Merger
Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0478 →
Change of Name
Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0179 →
Change of Name
Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0192 →
Merger
Feb 15, 2016
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 037820/0360 →
Merger
Feb 15, 2016
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 037820/0324 →
Change of Name
Feb 15, 2016
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 038020/0258 →
Assignment of Assignor's Interest
Dec 10, 2018
From: ASTRAZENECA AB
To: COVIS PHARMA B.V.
Reel/Frame 047761/0435 →
Security Interest
Dec 20, 2018
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 047834/0926 →
Security Interest
Mar 12, 2020
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 052095/0262 →
Release of Security Interest
Mar 17, 2020
From: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: COVIS PHARMA B.V.
Reel/Frame 052142/0961 →
Business Transfer and Contribution Agreement
Dec 16, 2020
From: COVIS PHARMA B.V.
To: COVIS PHARMA GMBH
Reel/Frame 054793/0416 →
Security Interest
Feb 22, 2021
From: COVIS PHARMA GMBH
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 055354/0063 →
Notice of Grant of Security Interest in Intellectual Property (First Lien)
Jan 4, 2022
From: COVIS PHARMA GMBH
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058640/0787 →
Release of Security Interest
Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA GMBH
Reel/Frame 059043/0226 →
Release of Security Interest
Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA B.V.
Reel/Frame 059043/0239 →
Notice of Grant of Security Interest in Intellectual Property (Second Lien)
Feb 18, 2022
From: COVIS PHARMA GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 059232/0514 →